Acrivon Therapeutics Inc (ACRV)
8.285
-0.78
(-8.65%)
USD |
NASDAQ |
May 01, 16:00
8.285
0.00 (0.00%)
After-Hours: 20:00
Acrivon Therapeutics Cash from Investing (TTM): 50.72M for Dec. 31, 2023
Cash from Investing (TTM) Chart
Historical Cash from Investing (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 50.72M |
September 30, 2023 | -64.89M |
June 30, 2023 | -111.52M |
Date | Value |
---|---|
March 31, 2023 | -131.93M |
December 31, 2022 | -141.68M |
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (TTM) Range, Past 5 Years
-141.68M
Minimum
Dec 2022
50.72M
Maximum
Dec 2023
-79.86M
Average
-111.52M
Median
Jun 2023
Cash from Investing (TTM) Benchmarks
MyMD Pharmaceuticals Inc | 1.846M |
Vincerx Pharma Inc | 41.50M |
GlycoMimetics Inc | -0.0214M |
Immunic Inc | 9.462M |
Skye Bioscience Inc | 6.596M |